Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07POC
|
|||
| Former ID |
DAP001010
|
|||
| Drug Name |
Erlotinib
|
|||
| Synonyms |
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Approved | [1], [2] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [1], [3] | ||
| Colon cancer [ICD-11: 2B90.Z] | Phase 2 | [1], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
OSI Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23N3O4
|
|||
| Canonical SMILES |
COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
|
|||
| InChI |
1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
|
|||
| InChIKey |
AAKJLRGGTJKAMG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 183321-74-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
826174, 6593089, 7885946, 8035065, 10258448, 14720343, 14878691, 21317842, 26757996, 33500421, 46508021, 47957324, 50068213, 50100099, 50405936, 53788276, 57395323, 68530774, 85171065, 85261833, 85267493, 87350514, 92308781, 92717787, 93581027, 94568883, 103177459, 103905339, 104425943, 104831334, 117695448, 117866919, 118049695, 124893165, 124893166, 125001915, 125343507, 126622002, 126653679, 126670959, 126670960, 127301426, 127301427, 127301428, 127301429, 127301430, 127301431, 127301432, 127301433, 127301434
|
|||
| ChEBI ID |
CHEBI:114785
|
|||
| ADReCS Drug ID | BADD_D00800 ; BADD_D00801 | |||
| SuperDrug ATC ID |
L01XE03
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Erlotinib (adjusted p-values: 5.68E-03). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Erlotinib (adjusted p-values: 2.03E-03). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920). | |||
| REF 2 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | |||
| REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.